食管癌的中西医结合诊疗现状
Current Status of Integrated Traditional Chinese and Western Medicine in the Treatment of Esophageal Cancer
DOI: 10.12677/tcm.2024.134129, PDF,   
作者: 张 鹏, 王 珍, 董国华*：南京中医药大学附属南京市中医院胸心血管外科，江苏 南京；吴艺豪：南京中医药大学附属中西医结合医院胸心血管外科，江苏 南京；李家齐：黑龙江中医药大学研究生院，黑龙江 哈尔滨
关键词: 食管癌；中西医结合；流行病学；外科手术；化疗；Esophageal Cancer； Integrated Traditional Chinese and Western Medicine； Epidemiology； Surgery； Chemotherapy
摘要: 近年来，食管癌于我国呈现高发态势，因其早期发病隐匿、症状相对不明显的特点，往往在发现时就已进入中晚期。然而单一的治疗方式对中晚期食管癌的疗效较差，目前食管癌的治疗方案以手术治疗、放疗、化疗、免疫治疗等为主的多学科综合治疗，但治疗后的5年生存率仍不高。因此，本文通过分析已发表的相关文献，结合临床经验，总结食管癌中西医结合治疗的现状，以供临床参考。
Abstract: In recent years, esophageal cancer has shown a high incidence in China. Due to its insidious early onset and relatively insignificant symptoms, it often enters the middle and late stages when it is found. However, the efficacy of single treatment modality for middle and advanced esophageal cancer is poor. Currently, the treatment plan for esophageal cancer is multidisciplinary comprehensive treatment mainly based on surgery, radiotherapy, chemotherapy, immunotherapy, etc., but the 5-year survival rate after treatment is still not high. Therefore, this paper summarizes the current status of integrated traditional Chinese and Western medicine treatment of esophageal cancer by analyzing the published relevant literature and combining clinical experience for clinical reference.
文章引用：张鹏, 王珍, 吴艺豪, 李家齐, 董国华. 食管癌的中西医结合诊疗现状[J]. 中医学, 2024, 13(4): 822-828. https://doi.org/10.12677/tcm.2024.134129

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] 缪伟刚, 周金意, 苏健, 等. 2018年江苏省食管癌流行现状及2009-2018年变化趋势分析[J]. 中国肿瘤, 2023, 32(8): 573-581.
[3] Wang, Y.C., Mcpherson, K., Marsh, T., et al. (2011) Obesity 2: Health and Economic Burden of the Projected Obesity Trends in the USA and the UK. The Lancet, 378, 815-825. [Google Scholar] [CrossRef] 
[4] Arnal, M.J.D. (2015) Esophageal Cancer: Risk Factors, Screening and Endoscopic Treatment in Western and Eastern Countries. World Journal of Gastroenterology, 21, 7933-7943. [Google Scholar] [CrossRef] [PubMed]
[5] 刘健. 手术对比化疗治疗食管癌的循证研究[D]: [博士学位论文]. 兰州: 兰州大学, 2016.
[6] 武鸣, 周金意. 江苏省恶性肿瘤报告(2020) [M]. 南京: 东南大学出版社, 2021.
[7] 赫捷, 魏文强. 2020中国肿瘤登记年报[M]. 北京: 人民卫生出版社, 2022.
[8] Teng, Y., Xia, C., Li, H., et al. (2023) Cancer Statistics for Young Adults Aged 20 to 49 Years in China from 2000 to 2017: A Population-Based Registry Study. Science China Life Sciences, 67, 711-719. [Google Scholar] [CrossRef] [PubMed]
[9] 陈谦峰, 王河宝, 谢斌. 基于古医籍的噎膈病机探微[J]. 江西中医药大学学报, 2017, 29(4): 9-10, 22.
[10] 姜欣, 田叶红, 张巧丽, 等. 黄金昶治疗食管癌经验[J]. 中华中医药杂志, 2020, 35(1): 203-205.
[11] 安国辉. 张士舜主任医师治疗食管癌经验介绍[J]. 新中医, 2010, 42(12): 153-154.
[12] 崔慧娟, 张培宇. 张代钊治疗食管癌经验[J]. 中医杂志, 2011, 52(10): 821-823.
[13] 查永嫱, 孙东东, 潘立群. 食管癌术后中医药治疗研究进展[J]. 南京中医药大学学报, 2019, 35(6): 767-770.
[14] 周青, 孙长侠, 孙斐, 等. 启膈化痰合剂对顺铂治疗小鼠食管癌的减毒增效作用[J]. 中国现代中药, 2018, 20(3): 283-287.
[15] Miller, K.D., Nogueira, L., Devasia, T., et al. (2022) Cancer Treatment and Survivorship Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 409-436. [Google Scholar] [CrossRef] [PubMed]
[16] 郝媛媛, 程亮亮, 于显凤. 同步放化疗联合泰欣生治疗进展期食管癌的临床疗效及安全性分析[J]. 保健医学研究与实践, 2019, 16(4): 58-62.
[17] 宋春洋, 祝淑钗, 高丝娜, 等. 老年营养风险指数与接受根治性放化疗的老年食管癌患者的预后关系研究[J]. 中华放射医学与防护杂志, 2020, 40(12): 926-931.
[18] Datrino, L.N., Orlandini, M.F., Serafim, M.C.A., et al. (2022) Two-versus Three-Field Lymphadenectomy for Esophageal Cancer. A Systematic Review and Meta-Analysis of Early and Late Results. Journal of Surgical Oncology, 126, 76-89. [Google Scholar] [CrossRef] [PubMed]
[19] Davakis, S., Syllaios, A., Sdralis, E., et al. (2020) Hybrid Minimally-Invasive Esophagectomy for Esophageal Cancer: Clinical and Oncological Outcomes. Anticancer Research, 40, 1753-1758. [Google Scholar] [CrossRef] [PubMed]
[20] 国家卫生健康委员会. 食管癌诊疗规范(2018年版) [J]. 中华消化病与影像杂志(电子版), 2019, 9(4): 158-192.
[21] Nakamura, R., Omori, T., Takeuchi, H., et al. (2016) Salvage Endoscopic Resection as a Treatment for Locoregional Failure or Recurrence Following Chemoradiotherapy or Radiotherapy for Esophageal Cancer. Oncology Letters, 11, 3631-3636. [Google Scholar] [CrossRef] [PubMed]
[22] Welsch, J., Kup, P.G., Nieder, C., et al. (2016) Survival and Symptom Relief after Palliative Radiotherapy for Esophageal Cancer. Journal of Cancer, 7, 125-130. [Google Scholar] [CrossRef] [PubMed]
[23] Smyth, E.C., Lagergren, J., Fitzgerald, R.C., et al. (2017) Oesophageal Cancer. Nature Reviews Disease Primers, 3, Article No. 17048. [Google Scholar] [CrossRef] [PubMed]
[24] Depypere, L., Moons, J., Lerut, T., et al. (2016) Neoadjuvant Chemoradiation Treatment Followed by Surgery for Esophageal Cancer: There Is Much More than the Mandard Tumor Regression Score. Acta Chirurgica Belgica, 116, 149-155. [Google Scholar] [CrossRef] [PubMed]
[25] 关茜, 焦俊喆, 叶子豪, 等. 益脾扶正方联合化疗治疗中晚期食管癌21例[J]. 陕西中医药大学学报, 2019, 42(1): 150-154.
[26] 张颖慧, 谢雁鸣, 张寅, 等. 基于关联规则Apriori算法的真实世界复方苦参注射液治疗食管恶性肿瘤联用西药特征的研究[J]. 中药药理与临床, 2018, 34(4): 176-180.
[27] 谢学军. 加减参赭培气汤结合放疗治疗食管癌26例[J]. 中医研究, 2009, 22(7): 31-32.
[28] 周琳. 开郁化痰法联合TP方案治疗中晚期食管癌的临床疗效观察[D]: [硕士学位论文]. 哈尔滨: 黑龙江中医药大学, 2017.
[29] 尤夏. 益气调中法联合TS方案治疗晚期食管癌的临床研究[D]: [硕士学位论文]. 南京: 南京中医药大学, 2016.
[30] 李勇, 杨雪飞, 丁纪元, 等. 噎膈二号方治疗中晚期食管癌临床疗效观察[J]. 肿瘤学杂志, 2012, 18(5): 397-398.
[31] 弓树德. 补中益气汤加减治疗食管癌术后功能性腹泻的临床研究[D]: [硕士学位论文]. 南京: 南京中医药大学, 2018.
[32] 金玉婷. 补气活血汤联合免疫及化疗治疗气虚血瘀型食管癌的临床研究[D]: [硕士学位论文]. 合肥: 安徽中医药大学, 2023.
[33] 余倩慧, 刘夫艳, 尹刚, 等. 从动静辩证关系探讨补气活血药抗肿瘤转移的内涵[J]. 南京中医药大学学报, 2022, 38(9): 765-769.
[34] 张晓双, 陈希琦, 李轩, 等. 补气活血化瘀药调控Th1/Th2通路干预结直肠癌术后的研究进展[J]. 中国中西医结合外科杂志, 2021, 27(2): 355-357.